Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Profit After Tax (2016 - 2025)

Outlook Therapeutics has reported Profit After Tax over the past 8 years, most recently at -$13.5 million for Q4 2025.

  • Quarterly Profit After Tax rose 37.59% to -$13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$94.8 million through Dec 2025, down 102.11% year-over-year, with the annual reading at -$64.0 million for FY2025, 15.11% up from the prior year.
  • Profit After Tax was -$13.5 million for Q4 2025 at Outlook Therapeutics, up from -$14.8 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$13.5 million in Q4 2025 and troughed at -$46.4 million in Q1 2025.